Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill.
Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda.
J Allergy Clin Immunol. 2022 Jul;150(1):33-47. doi: 10.1016/j.jaci.2022.03.015. Epub 2022 May 20.
BACKGROUND & AIMS: Disease activity and severity of eosinophilic esophagitis (EoE) dictate therapeutic options and management, but the decision-making process for determining severity varies among practitioners. To reduce variability in practice patterns and help clinicians monitor the clinical course of the disease in an office setting, we aimed to create an international consensus severity scoring index for EoE.
A multidisciplinary international group of adult and pediatric EoE researchers and clinicians, as well as non-EoE allergy immunology and gastroenterology experts, formed 3 teams to review the existing literature on histology, endoscopy, and symptoms of EoE in the context of progression and severity. A steering committee convened a 1-day virtual meeting to reach consensus on each team's opinion on salient features of severity across key clinicopathologic domains and distill features that would allow providers to categorize disease severity.
Symptom features and complications and inflammatory and fibrostenotic features on both endoscopic and histologic examination were collated into a simplified scoring system-the Index of Severity for Eosinophilic Esophagitis (I-SEE)-that can be completed at routine clinic visits to assess disease severity using a point scale of 0-6 for mild, 7-14 for moderate, and ≥15 for severe EoE.
A multidisciplinary team of experts iteratively created a clinically usable EoE severity scoring system denominated "I-SEE" to guide practitioners in EoE management by standardizing disease components reflecting disease severity beyond eosinophil counts. I-SEE should be validated and refined using data from future clinical trials and routine clinical practice to increase its utilization and functionality.
嗜酸性食管炎(EoE)的疾病活动度和严重程度决定了治疗选择和管理方案,但确定严重程度的决策过程在不同医生之间存在差异。为了减少实践模式的变异性,并帮助临床医生在诊室环境中监测疾病的临床进程,我们旨在为 EoE 创建一个国际共识严重程度评分指数。
一个由成人和儿科 EoE 研究人员和临床医生以及非 EoE 过敏免疫和胃肠病学专家组成的多学科国际小组,分为 3 个小组,根据疾病的进展和严重程度,回顾 EoE 的组织学、内镜和症状的现有文献。一个指导委员会召开了为期 1 天的虚拟会议,就每个小组对关键临床病理领域的严重程度的显著特征的意见达成共识,并提炼出能够让提供者对疾病严重程度进行分类的特征。
症状特征和并发症以及内镜和组织学检查中的炎症和纤维性狭窄特征被整理成一个简化的评分系统——嗜酸性食管炎严重程度指数(I-SEE)——可以在常规就诊时使用 0-6 分的评分来评估疾病的严重程度,轻度为 0-2 分,中度为 3-6 分,重度为≥7 分。
一个多学科专家小组通过反复迭代创建了一个可用于临床的 EoE 严重程度评分系统,称为“ I-SEE”,通过标准化反映疾病严重程度的疾病成分,为 EoE 的管理提供指导,而不仅仅是嗜酸性粒细胞计数。I-SEE 应使用未来临床试验和常规临床实践的数据进行验证和完善,以提高其利用率和功能。